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A B S T R A C T
The folate cycle is an essential metabolic pathway in the cell, involved in nucleotide synthesis, maintenance of
the redox balance in the cell, methionine metabolism and re-methylation reactions. Standardised methods for
the measurement of folate cycle intermediates in different biological matrices are in great demand. Here we
describe a rapid, sensitive, precise and accurate liquid chromatographic–tandem mass spectrometric (LC–MS/
MS) method with a wide calibration curve range and a short run time for the simultaneous determination of
folate cycle metabolites, including tetrahydrofolic acid (THF), 5‑methyl THF, 5‑formyl THF, 5,10‑methenyl THF,
5,10‑methylene THF, dihydrofolic acid (DHF) and folic acid in different biological matrices. Extraction of folate
derivatives from soft and hard tissue samples as well as from adherent cells was achieved using homogenisation
in buffer, while extraction from the whole blood and plasma relied on the anion exchange solid-phase extraction
(SPE) method. Chromatographic separation was completed using a Waters Atlantis dC18 2.0×100mm, 3-μ
column with a gradient elution using formic acid in water (0.1% v/v) and acetonitrile as the mobile phases. LC
gradient started with 95% of the aqueous phase which was gradually changed to 95% of the organic phase
during 2.70min in order to separate the selected metabolites. The analytes were separated with a run time of
5 min at a flow rate of 0.300mL/min and detected using a Waters Xevo-TQS triple quadrupole mass spectro-
meter in the multiple reaction monitoring mode (MRM) at positive polarity. The instrument response was linear
over a calibration range of 0.5 to 2500 ng/mL (r2 > 0.980). The developed bioanalytical method was thor-
oughly validated in terms of accuracy, precision, linearity, recovery, sensitivity and stability for tissue and blood
samples. The matrix effect was compensated by using structurally similar isotope labelled internal standard (IS),
13C5‑methyl THF, for all folate metabolites. However, not all folate metabolites can be accurately quantified
using this method due to their high interconversion rates especially at low pH. This applies to 5,10‑methylene
THF which interconverts into THF, and 5,10‑methenyl‑THF interconverting into 5‑formyl‑THF. Using this
method, we measured folate cycle intermediates in mouse bone marrow cells and plasma, in human whole
blood; in mouse muscle, liver, heart and brain samples.
1. Introduction
Folic acid, or vitamin B9, is a water-soluble compound essential for
normal tissue growth and development [1]. It consists of a pteridine
ring, p‑aminobenzoate and a glutamyl moiety. Animal cells are not able
to synthesise folic acid; therefore, diet and microbiota are the sources of
this vitamin. After being transported into the cell, folic acid undergoes
poly-γ-glutamylation to retain within the cell, followed by stepwise
reduction by dihydrofolate reductase using NADPH to its active form of
tetrahydrofolate (THF), which can carry a one-carbon unit conjugated
to nitrogen at position 5 or 10 in the pteridine ring [2,3]. The most
common one-carbon donor for THF is serine [4]. THF with a bound
carbon unit can exist in several intermediates distinguished by different
oxidation states of the shuttled carbon. The transformation of one form
of THF to the other takes place during the folate cycle. Each THF in-
termediate fuels a certain metabolic pathway linked to the folate cycle.
As such, 5‑methyl THF donates the methyl group for methionine re-
generation in the methionine cycle and, therefore, for all re-methyla-
tion reactions in the cell; 5,10‑methylene THF is used in thymidylate
synthesis; and 10‑formyl THF is the source of formate and substrate in
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purine synthesis [5]. Chemical structures of the folate metabolites are
shown in Fig. 1. The oxidation of a shuttled carbon atom in the folate
cycle is accompanied by the production of NADPH, critical for defence
against oxidative stress and reductive biosynthesis in the cell [6]. The
folate cycle is especially important for highly proliferative cells [7].
However, not much is known about the tissue- and condition-specific
modulation of the folate cycle, including whether all THF intermediates
are present in equal amounts or the production of one form of THF can
overweigh production of the others. Progress in this area is hampered
by the absence of a sensitive quantitative method for the simultaneous
measurement of all THF intermediates from a single biological sample.
The main challenges in the analysis of these compounds are their in-
stability, pH-dependent interconversion and the varying length of the
poly‑γ‑glutamyl tail. Furthermore, endogenous folate metabolites are
present in very low amounts within biological matrices. Although a
number of publications described analytical methods for the determi-
nation of selected folate cycle metabolites [8–13], there is no standar-
dised method which could be used for the simultaneous determination
of all THF derivatives in different biological matrices. For instance, Jia
et al. quantitatively measured all folate metabolites except 5,10‑me-
thylene THF from human colonic mucosa samples using labelled iso-
tope compounds as the internal standard [9]. In addition, Odin et al.
measured 5,10‑methylene THF and 5‑methyl THF from colorectal mu-
cosa and tumour tissues [10]. Fazili et al. quantitatively determined
folate metabolites such as folic acid, 5‑methyl THF and 5‑formyl THF
from blood and serum samples using a solid-phase extraction technique
[11,12]. By contrast, Filip et al. analysed free and total folate in plasma
and red blood cells using a stable isotope dilution liquid chromato-
graphic–tandem mass spectrometric (LC–MS/MS) method in clinical
samples [13].
The primary objective of the present work, therefore, was to de-
velop a rapid, simple, accurate, precise and sensitive method for the
measurement of core folate cycle metabolites—folic acid, tetra-
hydrofolic acid, 5,10‑methenyl THF, 5,10‑methylene THF, 5‑formyl
THF, 5‑methyl THF and dihydrofolic acid—from different biological
matrices. To do so, we used tandem mass spectrometry, which emerged
as an established analytical technique for the analysis of metabolites
from complex biological samples. The key advantages of the LC–MS/MS
technology include its ability to accurately identify and quantify several
coenzyme species simultaneously.
2. Materials and methods
2.1. Chemicals, reagents and samples
Folate metabolites, including folic acid (purity > 98.5%), tetra-
hydrofolic acid (purity 95–98%), 5‑methyl THF (purity > 95%),
5‑formyl THF (purity > 99%), 5,10‑methenyl THF (purity > 97.5%),
5,10‑methylene THF (purity > 93%), dihydrofolic acid (purity
90–95%) and labelled internal standard 13C5‑methyl THF, were pur-
chased from Schricks Laboratory (Jona, Switzerland). LC–MS grade
acetonitrile and methanol (HiPerSolv) were obtained from VWR
International (Helsinki, Finland). Other chemicals, such as formic acid,
β‑mercaptoethanol, ascorbic acid, potassium hydroxide and a HEPES
buffer, were of high-grade purity and purchased from Sigma Aldrich
(St. Louis, MO, USA). Deionised water (18MΩ·cm at 25 °C) used for
solution preparation was made using a Milli-Q water purification
system procured from Merck Millipore (Billerica, MA, USA). Rat plasma
with heparin as the anticoagulant was purchased from Innovative
Research Laboratory (Novi, MI, USA). Whole human blood was pro-
cured from the Finnish Red Cross blood service (Helsinki, Finland).
Mouse heart, liver, brain and muscle tissue samples from CD5 mice 7- to
12-weeks old maintained on standard small rodent chow, were ob-
tained from Innovative Research Laboratory (Novi, MI, USA). Finally,
mouse bone marrow and mouse plasma samples were kindly donated
by Professor Anu Wartiovaara's laboratory (Biomedicum, University of
Helsinki, Finland). Each bone marrow sample was obtained from two
femur bones from a single animal. All biological samples were stored at
−80 °C until used.
Fig. 1. Chemical structures of the folate metabolites.
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2.2. Solution preparation
HEPES buffer with pH 8.0 was used to prepare stock solutions and
working solutions to prevent degradation of folate metabolites and to
maintain optimal conditions for deconjugase enzyme activity [9]. Stock
solutions for each metabolite were prepared at a final concentration of
0.5 mg/mL in a HEPES buffer at pH 8.0 (50mM HEPES buffer con-
taining 1% ascorbic acid (w/v) and 1% β‑mercaptoethanol (v/v), ad-
justed to pH 8.0 with potassium hydroxide). A working solution con-
taining all metabolites with a 5000 ng/mL concentration for each was
prepared in a HEPES buffer (pH 8.0). Calibration curve solutions were
prepared by serial dilution from the working solution in a HEPES buffer
(pH 8.0) to yield a concentration range of 0.5 to 2500 ng/mL. An in-
ternal standard (13C5‑methyl THF) dilution solution (400 ng/mL) was
prepared from its stock solution (0.5 mg/mL) in a HEPES buffer
(pH 8.0). All standard solutions were stored at −20 °C and were pro-
tected from light during use and storage. We found these solutions to be
stable and used them for method development and validation. An elu-
tion solution was prepared by mixing seven parts 1% v/v formic acid
and three parts of an acetonitrile/methanol (1/1, v/v) mixture, then
adjusting the solution to pH 5.0. A HEPES buffer at pH 8.0 and a HEPES
buffer at pH 5.0, respectively, were used as the extraction buffer for the
tissue and whole blood extraction protocol.
2.3. Preparation of folate deconjugase
Folate-free rat plasma was used as a source of pteroylpoly‑γ‑glutamate
hydrolase for the deconjugation of the polyglutamate tail from THF deri-
vatives to convert them to the monoglytamate forms [10]. We added
750mg charcoal to 15mL rat plasma followed by incubation with mixing
for 1 h, at room temperature (RT) and centrifugation at 14,000 rpm for
20min. Treated rat plasma was filtered through a 0.2-μm GHP membrane
filter (Pall life sciences, Washington, NY, USA). After that rat plasma was
tested to make sure it is free of folate, aliquots were made and stored at
−20 ± 5 °C until used.
2.3.1. Extraction protocol for tissue samples and adherent cells
An aliquot of 40 mg frozen tissue was transferred to homogenisation
tubes (Bertin Technologies, France) with 1.4-mm ceramic (zirconium
oxide) beads. A total of 20 μL of an internal standard dilution solution
(400 ng/mL) was added and the samples were equilibrated on ice for
2min. Next, 450 μL of an extraction buffer (HEPES buffer pH 8.0) was
added to the homogenisation tubes and the samples were vortexed for
20 s. Tissue samples were homogenised using a tissue homogeniser
(Bertin Technologies, France) over three cycles of 30 s at 5500 rpm each
with a 10-s pause interval between cycles. After homogenisation, 40 μL
of charcoal-treated rat plasma was added and samples were incubated
at 37 °C for 3 h for folate deconjugation followed by centrifugation at
14,000 rpm for 15min at 4 °C. After centrifugation, 300 μL of super-
natant was passed through a 10-kDa cut-off filter (Sartorius Stedim
Biotech, Germany) at 14,000 rpm for 30min at 4 °C, and the filtrate was
collected for injection into the chromatographic system for folate ana-
lysis.
The same protocol was used for the extraction of folate derivatives
from adherent cell pellets (approximately 1 million cells). However,
instead of homogenisation, samples were sonicated and vortexed for
30 s over three cycles to break apart the cell pellets after the addition of
internal standards (IS) and a HEPES buffer at pH 8.0.
2.3.2. Extraction protocol for whole blood
The tissue sample preparation protocol was ineffective for the whole
blood and plasma samples due to the low recovery of folates. We,
therefore, used an ion-exchange solid-phase extraction (SPE) to extract
folate derivatives from these sample matrices. First, 20 μL of an internal
standard solution (400 ng/mL) was added to 40 μL of whole blood,
vortexed for 20 s and equilibrated for 2min on ice. Next, 850 μL of a
HEPES buffer (pH 5.0) (prepared as in Section 2.2, pH adjusted with
potassium hydroxide) was added as the extraction buffer followed by
the addition of 40 μL of charcoal-treated rat plasma. Samples were then
incubated at 37 °C for 3 h for folate deconjugation. The samples were
purified using strong anion exchange cartridges (StrataX-A) in a 96-well
format with a 30-mg/mL sorbent mass (Phenomenex, Torrance, CA,
USA). Conditioning of SPE cartridges was completed using 1mL me-
thanol followed by equilibration with 1mL of 1% v/v formic acid in
water containing 1% (w/v) ascorbic acid. Samples were loaded on SPE
cartridges. Then, SPE cartridges were washed twice with 1mL of 1%
ascorbic acid (w/v) followed by drying of the SPE cartridges under a
vacuum. Finally, samples were eluted with 0.5mL of an elution solution
and injected into the chromatographic system for folate analysis.
2.4. Instrument and analytical conditions
The final analysis of the folates was performed on a UHPLC–MS/MS
system consisting of a Waters Acquity UHPLC coupled to a Xevo-TQS
triple quadrupole mass spectrometer equipped with an electrospray
ionisation probe (Waters Corporation, Milford, MA, USA).
Chromatographic separation was completed using an Atlantis dC18
reversed-phase analytical column (2.0×100mm, 3-μ particles) from
Waters (Milford, MA, USA). Gradient elution with a flow rate of
0.300mL/min was carried out using 0.1% formic acid in water (v/v) as
mobile phase A and acetonitrile as mobile phase B. The elution was
initiated with an isocratic step of 95% of mobile phase A maintained
until 0.33 min and then gradually increasing the proportion of mobile
phase B to 95% over the next 2.70min. Next, the mobile phase was
immediately adjusted to its initial composition during the next
2.30min, with a total analysis time for a single injection of 5min. The
column oven and auto-sampler temperatures were set to 40 ± 3 °C and
5 ± 3 °C, respectively. We used an injection volume of 5 μL for the
sample extract. The auto-sampler was used to perform a partial loop
with a needle overfill injection for samples and standards. Positive
electrospray ionisation was used for the detection of folate metabolites.
The protonated molecular ions [M+H]+ of the folates were selected as
the precursor ions, since these produced the highest response during
optimisation of the instrument parameters. One specific mass transition
(m/z) was chosen for each compound using the multiple reaction
monitoring mode (MRM) function of the instrument for quantitation.
Table 1
Chemical formula and mass-dependent parameters for folate metabolites.
Compound name Chemical formula Mass transition (quantifier) Mass transition (qualifier) Cone voltage (eV) Collision voltage (V)
Folic acid C19H19N7O6 442.20→ 176.10 442.20→ 295.10 22 36
Tetrahydrofolic acid (THF) C19H23N7O6 446.20→ 299.20 446.20→ 120.02 26 18
5,10‑Methylene THF C20H23N7O6 458.20→ 311.20 458.20→ 166.10 24 18
5,10‑Methenyl THF C20H20N7O6 456.00→ 412.00 456.00→ 282.15 18 30
5‑Formyl THF C20H23N7O7 474.20→ 327.20 474.20→ 299.20 30 18
5‑Methyl THF C20H25N7O6 460.20→ 313.20 460.20→ 180.10 40 18
Dihydrofolic acid C19H21N7O6 444.00→ 178.00 444.00→ 136.00 60 30
13C5‑Methyl THF C1513C5H23N7O6 465.20→ 313.20 – 40 18
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The optimised compound-dependent mass parameters (i.e., cone vol-
tage and collision energy) and the MRM transitions are listed in Table 1.
The optimised source-dependent parameters, such as capillary voltage,
desolvation temperature, desolvation gas flow, cone gas flow and col-
lision gas flow, were maintained constantly at 2.92 kV, 500 °C, 600 L/h,
150 L/h and 0.15mL/min, respectively, throughout analysis. High-
purity nitrogen (purity > 99.9%) and argon (purity 99.998%) were
used as the desolvation and collision gases, respectively. The MRM
acquisition mode was selected for the quantification of metabolites with
an individual span time of 0.1 s provided in their individual MRM
channels. The dwell time was calculated automatically based on the
region of the retention time window, the number of MRM functions and
the number of data points required forming a peak. We used Mass Lynx
4.1 software for instrument control and data acquisition. Quantification
of the analytes was completed using the peak area ratio (area of me-
tabolite/area of IS) and a linear least-squares regression curve with a
weighting factor of 1/x2.
2.5. Validation
The developed method was validated according to the European
Medicines Agency (EMA) guidelines for bioanalytical method valida-
tion in terms of linearity, precision, accuracy, limit of detection (LOD),
limit of quantification (LOQ), recovery, matrix effect and stability [14].
The homogenisation and SPE protocols were followed separately to
prepare all tissue samples and whole blood samples, respectively, for
each precision and accuracy batch, and for other experiments during
method validation. Quality control (QC) samples at high (HQC, 800 ng/
mL), middle (MQC, 400 ng/mL) and low (LQC, 1.0 ng/mL) concentra-
tion levels were prepared by spiking the standard solution in the re-
spective homogenised biological matrices to complete all method va-
lidation experiments. Nevertheless, these matrices contain naturally
occurring endogenous folates and, thus, the concentration of the non-
spiked samples was always subtracted from the concentration of the
spiked samples. Complete validation was performed for the muscle
tissue and whole blood samples. Likewise, partial validation, including
inter- and intra-day precision, accuracy and recovery, was completed
for other tissue types (liver, heart and brain) and adherent cell samples
to check method performance. An aqueous calibration curve was used
to calculate the concentration values during method validation. A
system suitability experiment was performed by injecting six con-
secutive injections of level 5 with a concentration of 10 ng/mL at the
start of method validation to check instrument performance and re-
sponse reproducibility in terms of the peak area for each folate meta-
bolite. We observed a % coefficient of variation (CV) for the system
suitability within the range of 0.60% to 2.17%.
2.5.1. Auto-sampler carryover
An auto-sampler carryover experiment was performed at the start of
method validation to check the carryover of the highest standard so-
lution (ULOQ) in a blank matrix (STD BL) at RT of analytes. To check
the auto-sampler carryover blank sample, ULOQ and lower limit of
quantification (LLOQ) were processed as per the extracted sample
preparation. These samples were acquired by auto-sampler in a se-
quence of STD BL, ULOQ, STD BL and LLOQ in order to evaluate the
carryover. The acceptance criteria for carryover were set at 20% of the
peak area corresponding to the LLOQ level as per the EMA guidelines
for bioanalysis.
2.5.2. Linearity, accuracy and precision
To determine the linearity, accuracy and precision, three precision
and accuracy batches (P&A) consisting of one STD BL (blank matrix),
STD 1 to STD 12, six sets each of HQC, MQC and LQC or HQC and LQC
were performed on three separate days. All the samples including QCs
were prepared freshly on each analysis day. The calibration curve was
constructed by plotting the peak area ratio (standard/labelled standard)
versus the concentration at a range of 0.5 to 2500 ng/mL; the linearity
of the method was determined by using a 1/x2 weighted least-squares
regression analysis of a normal plot associated with a 12-point standard
curve. The accuracy and precision were evaluated using QCs prepared
and analysed on three separate days. The accuracy was evaluated by
measuring the mean accuracy at each concentration level of the cali-
bration curve standard and QCs, calculated as the measured value di-
vided by the nominal value. The inter- and intra-batch variability was
calculated by measuring % CV at each concentration level of QCs.
2.5.3. Recovery and matrix effect
The recovery and matrix effect experiments were performed at
high-, middle- and low-concentration levels. The analytes were spiked
either before (spiked samples) or after (post-spiked samples) extraction
at the concentration equivalent to those in the low-, middle- and high-
QC extracted samples (n= 6 at each level). Additionally, analytes were
spiked in an aqueous solvent to obtain samples free of the matrix. The
recovery was calculated using the ratio of the mean peak area of the
spiked samples to the mean peak area of the post-spiked samples. The
matrix effect was evaluated by calculating a matrix factor to check the
variability. The mean peak area in the presence of matrix ions (area of
post-spiked samples) and the mean peak area in the absence of matrix
ions (area of aqueous spiked samples) was calculated. The matrix factor
was calculated by dividing the mean peak area in the presence of matrix
ions by the mean peak area in the absence of matrix ions.
2.5.4. Stability
Different stabilities, such as wet extract stability, freeze–thaw sta-
bility and stock solution stability, were determined during validation.
Wet extract stability was assessed using the re-injection of samples
stored in the auto-sampler. After a full P&A batch was run, six replicates
of HQC and LQC vials were kept in the auto-sampler at 5 °C. To de-
termine the stability, the same samples in the same sequence were re-
injected with fresh QC samples, and the results were compared. The
freeze–thaw stability was evaluated during up to three cycles by
freezing and thawing the spiked samples stored at −80 °C. Three re-
plicates of QCs were stored at −80 °C and after 24 h, these samples
were retrieved and thawed at room temperature. These samples were
stored back in freezer for freezing and after 12 h again retrieved and
thawed at room temperature. This step was repeated again and after
that the samples were analysed. We assessed the stability by comparing
the concentration against the freshly spiked samples. Stock solution
stability was evaluated by comparing the mean peak area of fresh stock
solutions to the stored stock solutions stored at −20 ± 5 °C.
2.5.5. Limit of detection and limit of quantification
LOD and LOQ were defined as the lowest analyte concentrations
yielding a signal-to-noise (S/N) ratio of 3 and 10, respectively. We have
used empirical approaches to minimise the random error and estimates
the expected precision of a series of measurements of analytical signal
for measurement of LOD and LOQ values [10,15]. The experiment
commenced with the serial dilution of the final extract of the spiked
samples. These samples were then analysed along with the blank
samples in replicates of three for individual concentrations using each
extraction method.
3. Results and discussion
3.1. Method development
3.1.1. Method optimisation
We employed the UHPLC–MS/MS method with electro spray ioni-
sation due to the selectivity, sensitivity and reproducibility of this
technique. The use of positive ESI resulted in good ionisation of the
analytes and [M+H]+ ions were chosen as precursor ions. The se-
lection of the product ion producing the highest response further
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improved the selectivity and sensitivity of the method. Different sta-
tionary phase and mobile phase compositions were tested, and finally
the most optimal separation, peak shape and response was obtained in
an Atlantis dC18 2.0×100mm, 3-μ column with 0.1% formic acid in
water (v/v) and an acetonitrile mobile phase in the gradient elution
mode.
Folate metabolites are unstable since they are very sensitive to light,
oxidants and pH. Additionally, they are interconvertible depending
upon the pH of the extraction buffer [8–10]. Most folate metabolites are
stable between pH 5 and 10 when not exposed to elevated tempera-
tures. Ascorbic acid along with β‑mercaptoethanol has been shown to
prevent interconversion and the further oxidative degradation of folate
metabolites [8,10]. Thus, all stock and working solutions were prepared
in a HEPES buffer (pH 8.0) containing both of the abovementioned
chemicals. We found that the standard solutions were stable up to two
months after storage at −20 °C. However, they were stored at a high
concentration to prevent degradation and interconversion since the
stability of 5,10‑methylene THF, THF and 5,10‑methenyl THF is con-
centration-dependent [10]. Most endogenous folates are present as
polyglutamates in biological materials, and thus their cleavage to
monoglutamates is necessary in order to quantify pure folate metabo-
lites [11,12]. We used charcoal-treated rat plasma as a source of pter-
oylpoly‑γ‑glutamylcarboxypeptidase for folate deconjugation since this
enzyme has an optimum pH at approximately 7.5. For deconjugation,
we incubated samples for 3 h at 37 °C as in previous studies [10–12].
For instance, Fazili et al. [12] demonstrated that the intensity of the
signal was high for all folate metabolites tested, particularly for 5‑me-
thyl THF, in samples incubated for 3 h. We selected homogenisation
method for extraction since it is simple and minimize rapid degradation
of folate metabolites. We chose a HEPES buffer (pH 8.0) as the ex-
traction buffer after testing various buffer compositions. We obtained
an acceptable chromatography and sensitivity using this buffer, which
was important since the final extract was injected without further
treatment. Additionally, we found that the folates of interest were
stable in a HEPES buffer (pH 8.0) and obtained a satisfactory recovery
and reproducibility for the tissue and cell samples. However, we ob-
served a low recovery and high matrix effect for whole blood samples
using the same protocol and, thus, chose SPE extraction to achieve
cleaner extracts and an increased recovery. Almost all folates have an
acidic pKa value; we, therefore, selected SPE with a strong anion ex-
change mechanism. Various SPE cartridges from different vendors were
tested to obtain a good extraction efficiency. The best results were
obtained using Strata-X anion exchange SPE cartridges. Furthermore,
for the optimisation of the extraction method, we combined several
extraction buffers, washing solutions and elution solutions to obtain an
adequate recovery with a minimum loss of folate metabolites. In gen-
eral, a low pH is required to retain folates using SPE since it also enables
the release of protein-bound folate. However, stability may become an
Fig. 2. Optimisation of sample volume for the reliable quantification of extracted folate metabolites from various biological samples (muscle, brain, heart and liver;
n= 6). The y axis shows the average concentration (ppb) of the respective folate metabolites.
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issue at a very low pH as endogenous 5,10‑methenyl THF converts to
10‑formyl THF and 5,10‑methylene THF converts to THF [9, 10]. A
HEPES buffer (pH 8.0) was ideal, preventing degradation and the loss of
folates, but recovery was very low perhaps due to the insufficient re-
tention of folates on SPE at this pH. Finally, adjusting the pH of the
HEPES extraction buffer to 5.0 proved a suitable compromise in order
to achieve sufficient recovery with less degradation and interconver-
sion. We encountered similar problems when optimising the pH during
elution, since acidic conditions were required for the ion exchange and
to elute the folate metabolites. We did not obtain 5,10‑methylene THF
at a low pH (pH 2–3) due to its instability during extraction with SPE,
while we obtained an acceptable recovery using an elution solution
with pH 5.0. Acetonitrile was added to the elution solution since it in-
creased the response of 5-formyl THF and 5‑methyl THF by almost 20%,
while the use of methanol lead to less noise in LC–MS. We used an
isotope labelled 5‑methyl THF as an internal standard to correct
for any potential loss of metabolites during sample preparation and
due to the matrix effect except during the interconversion of folate
metabolites. The matrix effect was found less often when using the
extraction method described above and did not affect the final
results due to the structural similarity of the internal standard for al-
most all folates.
3.1.2. Folate interconversion
To test folate interconversion, we selected the liver since the con-
centration of folates is highest there among tested tissues. Tissue sam-
ples were homogenised and 16 aliquots were made. Individual folate
standards were spiked into respective aliquots in two replicates. Two
aliquots were processed without spiking to check the endogenous
Fig. 3. Linearity in concentrations ranging from 0.5 to 2500 ng\mL of the calibration curve for folate metabolites with a weighing factor of 1/x2.
Table 2

























Folic acid 0.984 1.56 10.45 1.58 17.27 91.25
Tetrahydrofolic
acid (THF)
0.991 1.50 0.94 2.97 1.09 93.45
5,10‑Methylene
THF
0.988 3.51 0.98 3.26 2.13 92.05
5,10‑Methenyl
THF
0.991 5.73 1.60 4.11 2.70 95.41
5‑Formyl THF 0.998 4.50 8.47 6.75 10.96 93.07
5‑Methyl THF 0.994 6.74 8.79 8.58 6.51 91.18
Dihydrofolic
acid
0.997 8.67 10.94 12.45 14.68 86.64
a Lowest r2 value across three calibration sets during validation.
b Mean recovery.
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concentration of the folates. All samples were processed according to
the tissue protocol, and interference from the folate metabolites was
checked by examining their respective chromatograms. We observed
that approximately 27% of dihydrofolate is converted to folic acid;
approximately 40% of 5,10‑methylene THF is converted to THF and
2.3% of 5,10‑methenyl THF is converted to 5‑formyl THF. The high
conversion rate of 5,10‑methylene THF to THF might be due to the
acidic mobile phase.
Table 3
Results of recovery, intra- and inter-day precision of folate metabolites in human whole blood.
Compound name Linearity r2
valuea
Intra-day precision of high, middle and low
concentrations, %RSD




800 ng/mL 400 ng/mL 1.0 ng/mL 800 ng/mL 400 ng/mL 1.0 ng/mL
Folic acid 0.988 21.82 19.60 26.35 23.91 16.74 24.36 18.62
Tetrahydrofolic acid (THF) 0.988 7.04 9.18 12.54 20.44 9.80 16.54 76.90
5,10‑Methylene THF 0.994 30.39 26.76 28.54 36.69 34.41 32.54 123.56
5,10‑Methenyl THF 0.987 19.74 10.44 22.64 12.67 10.09 18.24 91.69
5‑Formyl THF 0.994 7.26 7.99 10.54 18.42 9.81 16.65 58.62
5‑Methyl THF 0.997 5.23 3.33 10.54 12.73 15.06 14.33 111.56
Dihydrofolic acid 0.995 NDb NDb NDb NDb NDb NDb NDb
a Lowest r2 value across three calibration sets during validation.
b Could not be determined from whole blood.
c Mean recovery.
Fig. 4. Chromatograms showing the peak shape, retention time and mass transition for all folate metabolites during muscle tissue sample analysis.
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3.1.3. Sample volume optimisation
In order to identify the minimum sample requirement, different
sample weights—that is, 10, 20 and 40mg—were tested for folate ex-
traction (Fig. 2). We found that for 10mg of tissue the concentration
values of folate metabolites were below the lower limit of quantifica-
tion (BLLOQ) or near LOQ (except in the liver tissue samples) with poor
chromatography results, particularly for 5‑formyl THF. However, the
chromatography and response performed well for all metabolites when
20mg of tissue was used. Yet, we found a response near LOQ for
5‑formyl THF and for 5‑methenyl THF in every tissue type except the
liver tissue samples. Thus, we calculated % CV of the response for all
metabolites to check for variation. We found that % CV of the response
fell to 18.31% for all metabolites across all tissue types except for
5,10‑methenyl THF (% CV=28.17% in the muscle tissue samples) and
for 5‑formyl THF (% CV=56.61% in the muscle tissue samples and
20.96% in the brain tissue samples). Yet, the % CV of the response was
12.49% for all metabolites across all tissue types with a 40mg tissue
weight. Thus, while we obtained an acceptable response and chroma-
tography profile using 20mg of tissue, 40mg yielded more accurate
and more reliable results.
3.2. Method validation
3.2.1. Auto-sampler carryover
We observed no significant carryover in the STD BL sample in this
experiment. We calculated the carryover as the percentage of the peak
area obtained from a blank sample chromatogram after injection with
ULOQ compared to the peak area of LLOQ. The peak area for the re-
tention time of the analytes in blank samples for all folate metabolites
reached no more than 20.00% of the LLOQ area.
3.2.2. Linearity, accuracy and precision
All calibration curves analysed during validation were linear for the
standards ranging from 0.5 to 2500 ng/mL. A straight-line fit was cal-
culated through the data points using least-squares regression analysis,
for which we observed a constant proportionality. Furthermore, the
back-calculated concentration of the standards fell within the accep-
tance criteria using the linear model. Different weighting factors,
Fig. 5. Chromatograms showing the peak shape, retention time and mass transition for all folate metabolites during whole blood sample analysis.
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including no weighting factor, 1/x and 1/x2, were applied to yield the
best linear regression model. We found a minimum absolute error ap-
plying the 1/x2 weighting factor. The regression coefficient values for
each folate metabolite were>0.980 (Fig. 3). The mean precision and
accuracy observed for all calibration curve standards did not exceed
15%. We calculated the precision for QC samples by measuring %RSD
at each QC concentration level. In general, intra- and inter-day preci-
sion (%RSD) values were within 15% for the muscle tissue samples and
within 25% for the whole blood samples. However, 5,10‑methylene
THF yielded high values of %RSD (up to 36.69%) for the whole blood
samples. Tables 2 and 3 provide the regression coefficients and intra-
and inter-day precision values for each folate metabolite for the muscle
tissue and whole blood, respectively. Figs. 4 and 5 show the chroma-
tograms for the folate metabolites during validation in the muscle tissue
and whole blood samples, respectively.
3.2.3. Recovery and matrix effect
Given that folate metabolites were relatively stable in a HEPES
buffer (pH 8.0), the recovery of all folate metabolites was excellent in
the muscle tissue samples, reaching values between 86.64% and
95.41% (Table 2). However, the recoveries were not as good in the
whole blood samples with values falling between 58.62% and 123.56%
(Table 3). This demonstrates the necessity of using the respective iso-
tope labelled internal standards to compensate for the loss of metabo-
lites and interconversion. In the whole blood samples, the recovery of
folic acid remained low because this compound ionised at a very low
pH. Additionally, we detected no dihydrofolic acid from the whole
blood samples due to its instability at a pH below 7. The matrix effect
values were acceptable in the muscle tissue varying from between 0.76
and 1.28. For the whole blood, we found matrix effect values of 0.54 to
0.70, except for 5,10‑methylene‑THF where the matrix factor value
reached 1.86. These results show that some matrix effect existed, which
could be compensated for using the labelled internal standard for each
analyte. However, the matrix effect variability at each level, as mea-
sured by the coefficient of variation, reached<25%, thus explaining
the reproducible results.
3.2.4. Stability
Because the folate metabolites are unstable, particularly 5,10‑me-
thenyl THF and 5,10‑methylene THF, we determined the stability of
folates in a final extract, in stock solutions and during the freeze–thaw
cycle. Folate metabolites extracted from the whole blood and tissue
samples were stable for 14 h at 5 °C after extraction. This did not hold
for 5,10‑methenyl THF or for 5,10‑methylene THF extracted from
whole blood since their stability fell outside the range of 85% and
115%. This demonstrates that pH and the presence of an antioxidant in
the elution solution does not completely protect folate from degrada-
tion and interconversion. Thus, the use of a one-to-one isotope labelled
internal standard is essential to compensate for the losses and ensures
the most accurate quantification. Furthermore, the freeze–thaw stabi-
lity after three freeze–thaw cycles was also acceptable without any
significant degradation of the folate metabolites. We found a stability
falling within 85% and 115% for each folate metabolite during the
freeze–thaw cycles, except for 5,10‑methylene THF and 5,10‑methenyl
THF, where stability reached 138.13% and 79.20%, respectively, in the
whole blood samples. All folate metabolite stock solutions were stable
for 2months at −20 °C. The stock solution stability fell within 85% and
115% for all folate cycle metabolites, except for dihydrofolic acid,
which reached 78.68%. Table 4 provides a summary of the stability
experiment results.
3.2.5. Limit of detection and limit of quantification
Using a signal-to-noise ratio of 3 as the cut-off, we calculated the
LOD values of the folate metabolites from the final extract of the muscle
tissue and whole blood samples as shown in Table 5. With a signal-to-
noise ratio of 10 as the cut-off, we obtained LOQ of 0.5 ng/mL for all
metabolites except for folic acid and dihydrofolic acid in the whole
blood samples, which could not be determined due to the low recovery
as mentioned in Table 5.
4. Biological sample analysis
We applied the developed and validated analytical method to de-
termine the distribution of folate cycle metabolites in human whole
blood and mouse plasma. We also examined different mouse tissue
samples including muscle, heart, liver and brain samples from CD5
mice 7- to 12-weeks old and bone marrow cells (Fig. 6). In the brain, the
total folate concentration, including all seven folate metabolites,
reached 0.045 μmol/g with a dominant concentration of THF (50% of
the total folate). The folate content in the heart tissue samples was
0.046 μmol/g with a THF concentration of 40% and a 5‑methyl THF
concentration of 35%. The total folate concentration in the muscle
tissue samples was 0.017 μmol/g, which is 2.7 times lower than in the
heart and muscle tissue samples, but with a similar relative amount of
5‑methyl THF accounting for 40% of the total folate pool, indicating a
high rate of re-methylation reactions in these tissues. The liver tissue
had the highest total folate content reaching values of 1.815 μmol/g
reflecting its high demands in one-carbon units especially for re-me-
thylation reactions. Since the liver has a high metabolic rate, the re-
lative amount of 5‑methyl THF is lower than that in the muscle tissue,
while the amount of its precursor 5,10‑methylene THF is elevated. The
total folate concentration measured in human blood was 155.59 ng/mL,
which is similar to the value of< 150 ng/mL reported in the Human
Metabolome Database (HMDB data). The total folate concentration in
Table 4
Summary of stability results for all folate cycle metabolites.
Compound
name
















Folic acid 101.88b 111.96b 95.25 93.31 98.89
Tetrahydrofolic
acid (THF)
105.75 102.36 94.70 91.26 98.72
5,10‑Methylene
THF
152.26 138.13 91.59 91.23 90.33
5,10‑Methenyl
THF
56.30 79.20 88.20 91.45 86.10
5‑Formyl THF 106.54 101.77 86.67 89.88 103.50
5‑Methyl THF 97.63 103.30 97.74 91.45 89.88
Dihydrofolic
acid
NDc NDc 86.25 92.45 78.68
a % mean stability.
b Stability at a high concentration level.
c Could not be determined from whole blood.
Table 5
















Folic acid 0.566 – 1.133 2.266
Tetrahydrofolic acid
(THF)
0.337 0.225 1.123 1.123
5,10‑Methylene THF 0.329 0.219 1.095 1.095
5,10‑Methenyl THF 0.547 0.656 1.094 1.094
5‑Formyl THF 0.317 0.317 1.056 1.056
5‑Methyl THF 0.327 0.218 1.089 1.089
Dihydrofolic acid 0.677 – 1.353 –
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the bone marrow cell samples reached 89 nmol/L with the highest re-
lative content of 5,10‑methenyl THF accounting for approximately 80%
of the total folate pool and 5,10‑methenyl THF is a precursor for
10‑formyl THF derivative. This finding likely results from bone mar-
row's characteristics as a highly proliferative tissue with an intensive
purine synthesis dependent on 10‑formyl THF. The average con-
centrations of the folate metabolites in the respective biological ma-
trices are provided in Table 6. We also measured the folate metabolites
in plasma using the blood extraction protocol. The total folate con-
centration in the plasma samples reached 1.094 nmol/L, including
0.491 nmol/L 5,10‑methenyl THF and 0.604 nmol/L 5‑methyl THF.
Such a high concentration of 5,10‑methenyl THF was not previously
reported, while plasma 5‑methyl THF is known as the common circu-
lating form of THF in the body.
5. Conclusions
We have developed and validated a rapid, sensitive, precise and
accurate method for measuring central folate cycle metabolites in dif-
ferent biological matrices with a wide calibration curve range
(0.5–2500 ng/mL) using liquid chromatography–tandem mass spectro-
metry. We simultaneously measured seven folate cycle metabolites
using a single method with a 5min run time. Because of the pH sen-
sitivity of folate cycle metabolites and their interconversions, achieving
an accurate quantification for all the metabolites using one method
remains challenging. However, we used a single isotope labelled
internal standard for all the measured folates achieving an acceptable
accuracy. However, we have not used matrix matched calibration curve
for calculating concentration values from samples, hence, estimation of
absolute values for folate metabolites is not possible with this method.
Overall, the validation results demonstrated that the proposed method
is reliable and fit-for-purpose for determining metabolites profiles in
various metabolomics studies. Furthermore, analysis of various tissue
samples can be performed simultaneously using a single protocol that
increases the sample throughput and minimises the workload. The de-
veloped method can potentially be used in various research fields
ranging from nutrition to cancer, and has already been successfully
applied to study folate metabolism in mitochondrial diseases [16].
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Table 6
Average distribution of folate metabolites in different biological matrices measured in mouse tissue, human whole blood and mouse bone marrow cells.
Muscle (μmol\g)a Brain (μmol\g)a Liver (μmol\g)a Heart (μmol\g)a Human blood (μmol\L)a Bone marrow cells (μmol\L)a
Folic acid 0.00018 0.00019 0.00084 0.00022 NDb NDb
Tetrahydrofolate 0.00492 0.02311 0.46603 0.01718 0.00233 0.00448
5,10‑Methenyl THF 0.00107 0.00025 0.00024 0.00103 0.02634 0.07260
5,10‑Methylene THF 0.00207 0.00736 0.84642 0.00942 0.19836 0.00343
5‑Formyl THF 0.00026 0.00059 0.01054 0.00068 0.02015 0.00074
5‑Methyl THF 0.00725 0.01157 0.48178 0.01638 0.08771 0.00736
Dihydrofolate 0.00100 0.00153 0.00942 0.00128 NDb NDb
a Mean value from six independent measurements.
b Could not be determined accurately from whole blood.
Fig. 6. Total folate pool distribution in various biological samples such as mouse heart, liver, QF muscle, brain, bone marrow cells and human blood. Averages across
six replicates were used to determine the folate metabolite distribution.
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